Robert N Schuck
Overview
Explore the profile of Robert N Schuck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taylor Z, Green F, Hossain N, Burckart G, Pacanowski M, Schuck R
Clin Pharmacol Ther
. 2024 Mar;
116(3):716-723.
PMID: 38493367
Pediatric drug dosing is challenged by the heterogeneity of developing physiology and ethical considerations surrounding a vulnerable population. Often, pediatric drug dosing leverages findings from the adult population; however, recent...
2.
Stern S, Hyland P, Pacanowski M, Schuck R
Drug Metab Dispos
. 2024 Jan;
52(3):159-170.
PMID: 38167410
Cytochrome P450 2D6 (CYP2D6) is responsible for the metabolism of up to 20% of small-molecule drugs and therefore, may impact the safety and efficacy of medicines in broad therapeutic areas....
3.
Bai J, Stinchcomb A, Wang J, Earp J, Stern S, Schuck R
Clin Pharmacol Ther
. 2023 Nov;
115(2):201-205.
PMID: 37984065
One of the goals of the Accelerating Rare Disease Cures (ARC) program in the Center for Drug Evaluation and Research (CDER) at the US Food and Drug Administration (FDA) is...
4.
Patel T, Marcus L, Horiba M, Donoghue M, Chatterjee S, Mishra-Kalyani P, et al.
Clin Cancer Res
. 2022 Oct;
29(5):838-842.
PMID: 36206041
On April 17, 2020, the FDA granted accelerated approval to pemigatinib (PEMAZYRE, Incyte Corporation) for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an...
5.
Adeniyi O, Hwang M, Sun J, Schuck R
Pharmacogenomics
. 2022 Apr;
23(7):397-404.
PMID: 35440173
Molecular alterations in drug targets may result in differential drug activity. Therefore, the authors aimed to characterize how molecular alterations in drug targets were assessed during drug development. The authors...
6.
Wang L, Wang J, Feng J, Doi M, Pepe S, Pacanowski M, et al.
Orphanet J Rare Dis
. 2022 Apr;
17(1):156.
PMID: 35382851
Background: The small patient populations inherent to rare genetic diseases present many challenges to the traditional drug development paradigm. One major challenge is generating sufficient data in early phase studies...
7.
Pacanowski M, Schuck R
Clin Pharmacol Ther
. 2021 Jul;
111(6):1202-1204.
PMID: 34278575
No abstract available.
8.
Wang L, Maxfield K, Guinn D, Madabushi R, Zineh I, Schuck R
Clin Pharmacol Ther
. 2020 Oct;
109(1):123-130.
PMID: 33022770
A key goal in drug development is optimized dosing for patients. Interactions between drug developers and regulatory scientists throughout development are important for the optimization of dosing and serve as...
9.
Horne H, Roscoe D, David Litwack E, Pathak A, Pandey J, Gallagher P, et al.
JCO Precis Oncol
. 2020 Sep;
3.
PMID: 32914013
Purpose: Next-generation sequencing (NGS) oncology panels are becoming integral in hospital and academic settings to guide patient treatment and enrollment in clinical trials. Although NGS technologies have revolutionized decision-making for...
10.
Boxer A, Gold M, Feldman H, Boeve B, Dickinson S, Fillit H, et al.
Alzheimers Dement
. 2019 Nov;
16(1):131-143.
PMID: 31668596
Introduction: Frontotemporal lobar degeneration (FTLD) is the most common form of dementia for those under 60 years of age. Increasing numbers of therapeutics targeting FTLD syndromes are being developed. Methods:...